January 2010
Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p4
Trade Publication
No abstract available.


Related Articles

  • Vectical Ointment.  // Formulary;Mar2009, Vol. 44 Issue 3, p71 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) on calcitriol, a vitamin D analogue for topical treatment of mild-to-moderate plaque psoriasis in adults, on January 23, 2009. The efficacy of the agent was assessed in two multicenter and observed that...

  • Fanapt.  // Formulary;Jun2009, Vol. 44 Issue 6, p164 

    The article offers information on Fanapt, a psychotropic agent. The drug, which received approval from the U.S. Food and Drug Administration on May 6, 2009, is useful in the treatment of acute schizophrenia . Also mentioned is the efficacy, safety measures required to be taken with the drug, and...

  • Aflibercept approved for wet AMD. Charters, Lynda // Ophthalmology Times;12/1/2011, Vol. 36 Issue 23, p1 

    The article reports on the approval of aflibercept by the U.S. Federal Drug Administration (FDA). It states that aflibercept is developed to treat neovascular age-related muscular degeneration (AMD). It notes that the recommended dosage of the drug for wet AMD is 2 milligram every 4 weeks for...

  • First Antihypertensive Drug Approved in Last 10 Years: Aliskiren. Elliott, William T. // Clinical Oncology Alert;Apr2007 Pharmacology Watch, p2 

    The article reports on the approval of the first of new class of antihypertensive drugs, and the first new antihypertensive medication to be approved in more than 10 years, by the U.S. Food and Drug Administration (FDA) in 2007. Aliskiren, an oral renin inhibitor, is a once-a-day oral agent that...

  • FDA advisers want more data about phenylephrine. Traynor, Kate // American Journal of Health-System Pharmacy;2/1/2008, Vol. 65 Issue 3, p193 

    The article reports on the contention that nasal congestion can be relieved with a 10-mg oral dose of phenylephrine according to the U.S. Food and Drug Administration (FDA) Nonprescription Drugs Advisory Committee. However, the advisers maintain that modern studies of the different dosages of...

  • QRxPharma receives US patent for MoxDuo IR.  // PharmaWatch: CNS;Jun2011, Vol. 10 Issue 6, p28 

    The article reports on the U.S. patent received by QRxPharma Ltd.'s MoxDuo IR drug. It notes that the clinical-stage specialty pharmaceutical company has obtained patent covering a proprietary dosing algorithm for patient converting from intravenous opioid to orally administered MoxDuo IR. It...

  • Pipeline preview.  // Formulary;Feb2010, Vol. 45 Issue 2, p41 

    The article discusses the status of various drugs in the U.S. Food and Drug Administration (FDA) approval process. The drugs recommended for approval include Carglumic acid for the treatment of patients with N acetyle glutamate sythetase (NAGS) deficiency and Miglustat for the treatment of...

  • New molecular entities: Tykerb.  // Formulary;Apr2007, Vol. 42 Issue 4, p214 

    The article reports on the approval of kinase inhibitor lapatinib in combination with capecitabine for the treatment of advanced or metastatic breast cancer. The efficacy of lapatinib has been tested in a randomized, phase three trial. Based on clinical trials, lapatinib can decrease left...

  • New biologic: Soliris.  // Formulary;Apr2007, Vol. 42 Issue 4, p215 

    The article reports on the approval of recombinant monoclonal antibody eculizumab from Alexion Pharmaceuticals Inc. for the treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis. Its efficacy is evaluated in a randomized placebo-controlled 26-week study, and a single-arm 52-week...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics